Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:FPRX's Cash-to-Debt is ranked higher than
76% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:FPRX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:FPRX' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Equity-to-Asset 0.87
NAS:FPRX's Equity-to-Asset is ranked higher than
79% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:FPRX: 0.87 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:FPRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.63  Med: 0.7 Max: 0.87
Current: 0.87
-2.63
0.87
Interest Coverage No Debt
NAS:FPRX's Interest Coverage is ranked higher than
69% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:FPRX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:FPRX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 10.50
Beneish M-Score: 34.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -329.18
NAS:FPRX's Operating Margin % is ranked lower than
64% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:FPRX: -329.18 )
Ranked among companies with meaningful Operating Margin % only.
NAS:FPRX' s Operating Margin % Range Over the Past 10 Years
Min: -329.18  Med: -195.38 Max: 75.56
Current: -329.18
-329.18
75.56
Net Margin % -250.98
NAS:FPRX's Net Margin % is ranked lower than
62% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. NAS:FPRX: -250.98 )
Ranked among companies with meaningful Net Margin % only.
NAS:FPRX' s Net Margin % Range Over the Past 10 Years
Min: -276.42  Med: -194.6 Max: 65.73
Current: -250.98
-276.42
65.73
ROE % -21.45
NAS:FPRX's ROE % is ranked higher than
61% of the 906 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:FPRX: -21.45 )
Ranked among companies with meaningful ROE % only.
NAS:FPRX' s ROE % Range Over the Past 10 Years
Min: -52.26  Med: -15.93 Max: 96.31
Current: -21.45
-52.26
96.31
ROA % -18.48
NAS:FPRX's ROA % is ranked higher than
59% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. NAS:FPRX: -18.48 )
Ranked among companies with meaningful ROA % only.
NAS:FPRX' s ROA % Range Over the Past 10 Years
Min: -53.75  Med: -22.36 Max: 70.93
Current: -18.48
-53.75
70.93
ROC (Joel Greenblatt) % -1870.94
NAS:FPRX's ROC (Joel Greenblatt) % is ranked lower than
70% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. NAS:FPRX: -1870.94 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:FPRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1870.94  Med: -624.88 Max: 6887.63
Current: -1870.94
-1870.94
6887.63
3-Year Revenue Growth Rate -23.00
NAS:FPRX's 3-Year Revenue Growth Rate is ranked lower than
76% of the 528 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:FPRX: -23.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:FPRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -46.5 Max: 19
Current: -23
0
19
GuruFocus has detected 3 Warning Signs with Five Prime Therapeutics Inc $NAS:FPRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:FPRX's 30-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:PFSCF, NYSE:BHVN, NAS:ACOR, NAS:ZIOP, NAS:AMRN, NAS:CLLS, NAS:AKAO, NAS:AMRI, NAS:EPZM, NAS:ASND, NAS:IMMU, OTCPK:PHMMF, OTCPK:STLLF, NAS:BYSI, NAS:FWP, NAS:INSY, NAS:ALDR, NAS:CHRS, NAS:RVNC, NAS:TGTX » details
Traded in other countries:5P8.Germany,
Headquarter Location:USA
Five Prime Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in discovering & developing novel protein therapeutics to improve lives of patients with serious diseases.

Five Prime Therapeutics is a biotechnology company focused on discovering and developing protein therapeutics for diseases. The company's product candidates address patient populations for which therapies are still needed. Its is focused on advancing its internal pipeline and retaining rights for products in targeted specialty markets. It also seeks to establish additional collaborations to supplement its internal development capabilities. These collaborations generate additional funding in order to further validate the company's technology.

Ratios

vs
industry
vs
history
PB Ratio 2.56
NAS:FPRX's PB Ratio is ranked higher than
68% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. NAS:FPRX: 2.56 )
Ranked among companies with meaningful PB Ratio only.
NAS:FPRX' s PB Ratio Range Over the Past 10 Years
Min: 1.77  Med: 3.3 Max: 8.42
Current: 2.56
1.77
8.42
PS Ratio 25.41
NAS:FPRX's PS Ratio is ranked lower than
68% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. NAS:FPRX: 25.41 )
Ranked among companies with meaningful PS Ratio only.
NAS:FPRX' s PS Ratio Range Over the Past 10 Years
Min: 0.99  Med: 7.33 Max: 50.54
Current: 25.41
0.99
50.54
EV-to-EBIT -4.78
NAS:FPRX's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.27 vs. NAS:FPRX: -4.78 )
Ranked among companies with meaningful EV-to-EBIT only.
NAS:FPRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -13.8  Med: -4.7 Max: 4.6
Current: -4.78
-13.8
4.6
EV-to-EBITDA -4.85
NAS:FPRX's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 18.63 vs. NAS:FPRX: -4.85 )
Ranked among companies with meaningful EV-to-EBITDA only.
NAS:FPRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -14.2  Med: -4.9 Max: 4.5
Current: -4.85
-14.2
4.5
Current Ratio 10.98
NAS:FPRX's Current Ratio is ranked higher than
82% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. NAS:FPRX: 10.98 )
Ranked among companies with meaningful Current Ratio only.
NAS:FPRX' s Current Ratio Range Over the Past 10 Years
Min: 1.96  Med: 8.38 Max: 11.6
Current: 10.98
1.96
11.6
Quick Ratio 10.98
NAS:FPRX's Quick Ratio is ranked higher than
83% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:FPRX: 10.98 )
Ranked among companies with meaningful Quick Ratio only.
NAS:FPRX' s Quick Ratio Range Over the Past 10 Years
Min: 1.96  Med: 8.38 Max: 11.6
Current: 10.98
1.96
11.6
Days Sales Outstanding 112.63
NAS:FPRX's Days Sales Outstanding is ranked lower than
75% of the 625 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. NAS:FPRX: 112.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
NAS:FPRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.9  Med: 7.81 Max: 112.63
Current: 112.63
3.9
112.63

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -19.30
NAS:FPRX's 3-Year Average Share Buyback Ratio is ranked lower than
68% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. NAS:FPRX: -19.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NAS:FPRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -179.4  Med: -72.15 Max: 0
Current: -19.3
-179.4
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.80
NAS:FPRX's Price-to-Net-Cash is ranked higher than
81% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 7.66 vs. NAS:FPRX: 2.80 )
Ranked among companies with meaningful Price-to-Net-Cash only.
NAS:FPRX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.69  Med: 3.71 Max: 7.44
Current: 2.8
2.69
7.44
Price-to-Net-Current-Asset-Value 2.64
NAS:FPRX's Price-to-Net-Current-Asset-Value is ranked higher than
82% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. NAS:FPRX: 2.64 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NAS:FPRX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.58  Med: 3.49 Max: 7.24
Current: 2.64
2.58
7.24
Price-to-Tangible-Book 2.57
NAS:FPRX's Price-to-Tangible-Book is ranked higher than
75% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: 4.93 vs. NAS:FPRX: 2.57 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NAS:FPRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.5  Med: 3.37 Max: 6.87
Current: 2.57
2.5
6.87
Price-to-Median-PS-Value 3.46
NAS:FPRX's Price-to-Median-PS-Value is ranked lower than
91% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. NAS:FPRX: 3.46 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NAS:FPRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2  Med: 1.08 Max: 6.02
Current: 3.46
0.2
6.02
Earnings Yield (Greenblatt) % -20.95
NAS:FPRX's Earnings Yield (Greenblatt) % is ranked lower than
73% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. NAS:FPRX: -20.95 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NAS:FPRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -33.7  Med: -10.5 Max: 70.3
Current: -20.95
-33.7
70.3

More Statistics

Revenue (TTM) (Mil) $34.31
EPS (TTM) $ -3.16
Beta4.88
Short Percentage of Float10.01%
52-Week Range $26.65 - 60.98
Shares Outstanding (Mil)28.79

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) -4.94
EPS without NRI ($) -4.94
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}